C
Carsten Müller-Tidow
Researcher at University Hospital Heidelberg
Publications - 560
Citations - 20526
Carsten Müller-Tidow is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Myeloid leukemia & Medicine. The author has an hindex of 64, co-authored 455 publications receiving 17033 citations. Previous affiliations of Carsten Müller-Tidow include University of Mainz & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer.
Ping Ji,Sven Diederichs,Wenbing Wang,Sebastian Böing,Ralf Metzger,Paul M. Schneider,Nicola Tidow,Burkhard Brandt,Horst Buerger,Etmar Bulk,Michael Thomas,Wolfgang E. Berdel,Hubert Serve,Carsten Müller-Tidow +13 more
TL;DR: The identification of MALAT-1 emphasizes the potential role of noncoding RNAs in human cancer and contributes to the identification of early-stage NSCLC patients that are at high risk to develop metastasis.
Journal ArticleDOI
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk,Weihsu Claire Chen,Stefanie Göllner,Louise Howell,Liqing Jin,Katja Hebestreit,Hans-Ulrich Klein,Andreea C. Popescu,Alan Kenneth Burnett,Ken I. Mills,Robert A. Casero,Laurence J. Marton,Patrick M. Woster,Mark D. Minden,Martin Dugas,Jean C.Y. Wang,Jean C.Y. Wang,John E. Dick,John E. Dick,Carsten Müller-Tidow,Kevin Petrie,Arthur Zelent +21 more
TL;DR: Data identify LSD1 as a therapeutic target and strongly suggest that it may contribute to AML pathogenesis by inhibiting the normal pro-differentiative function of ATRA, paving the way for new combinatorial therapies for AML.
Journal ArticleDOI
The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.
Lars Henning Schmidt,Tilmann Spieker,Steffen Koschmieder,J Humberg,Dominik Jungen,Etmar Bulk,Antje Hascher,Danielle Wittmer,Alessandro Marra,Ludger Hillejan,Karsten Wiebe,Wolfgang E. Berdel,Rainer Wiewrodt,Carsten Müller-Tidow +13 more
TL;DR: In situ hybridization on paraffin-embedded lung cancer tissue probes revealed that high MALAT-1 RNA expression in squamous cell carcinoma of the lung was associated with a poor prognosis, and data indicate that MALat-1 expression levels are associated with patient survival and identify tumor-promoting functions of MALatin 1.
Journal ArticleDOI
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Ashley Hamilton,G. Vignir Helgason,Mirle Schemionek,Bin Zhang,Svetlana Myssina,Elaine K. Allan,Franck E. Nicolini,Carsten Müller-Tidow,Ravi Bhatia,Valerie G. Brunton,Steffen Koschmieder,Tessa L. Holyoake +11 more
TL;DR: It is suggested that CML stem cell survival is Bcr-Abl kinase independent and curative approaches in CML must focus on kinase-independent mechanisms of resistance.
Journal ArticleDOI
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Röllig,Hubert Serve,Andreas Hüttmann,Richard Noppeney,Carsten Müller-Tidow,Utz Krug,Claudia D. Baldus,Christian Brandts,Volker Kunzmann,Hermann Einsele,Alwin Krämer,Kerstin Schäfer-Eckart,Andreas Neubauer,Andreas Burchert,Aristoteles Giagounidis,Stefan W. Krause,Andreas Mackensen,Walter E. Aulitzky,Regina Herbst,Mathias Hänel,Alexander Kiani,Norbert Frickhofen,Johannes Kullmer,Ulrich Kaiser,Hartmut Link,Thomas Geer,A. Reichle,Christian Junghanß,Roland Repp,Frank Heits,Heinz Dürk,Jana Hase,Ina-Maria Klut,Thomas Illmer,Martin Bornhäuser,Markus Schaich,Stefani Parmentier,Martin Görner,Christian Thiede,Malte von Bonin,Johannes Schetelig,Michael Kramer,Wolfgang E. Berdel,Gerhard Ehninger +43 more
TL;DR: This randomised, double-blind, placebo-controlled, phase 2 trial investigated the efficacy and tolerability of sorafenib versus placebo in addition to standard chemotherapy in patients with acute myeloid leukaemia aged 60 years or younger.